

**Amendments to the specification:**

Kindly amend the paragraph appearing on page 56, lines 8-15, as follows:

Preparation Example 1

50 mg of the compound obtained in Example-~~21~~ 2 was dissolved in 50 mL of Japan Pharmacopoeia distilled water, and Japan Pharmacopoeia distilled water was added to bring the total to 100 mL. The solution was aseptically filtered, and 1 mL portions of the solution were then used to fill injection vials under aseptic conditions, lyophilized, and sealed.

Kindly amend the paragraph appearing on page 56, lines 16-23, as follows:

Preparation Example 2

100 mg of the compound obtained in Example-~~21~~ 2 was dissolved in 50 mL of Japan Pharmacopoeia distilled water, and Japan Pharmacopoeia distilled water was added to bring the total to 100 mL. The solution was aseptically filtered, and 1 mL portions of the solution were then used to fill injection vials under aseptic conditions, lyophilized, and sealed.

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of claims:**

Claim 1 (currently amended): An isolated and purified oxytocin secretion regulator, comprising a ligand peptide, or salt thereof, for a G protein-coupled receptor protein, phGR3.

Claim 2 (currently amended): ~~[[An]]~~ The isolated and purified oxytocin secretion regulator according to Claim 1, wherein the ligand peptide, or salt thereof, for a G protein-coupled receptor protein is a polypeptide, or an amide or an ester or a salt thereof, containing an amino acid sequence ~~that is the same or substantially the same as~~ has at least 80% identity to the amino acid sequence represented by SEQ ID NO: 44.

Claim 3 (currently amended): ~~[[An]]~~ The isolated and purified oxytocin secretion regulator according to Claim 2, wherein the amino acid sequence represented by SEQ ID NO: 44 is selected from the group consisting of SEQ ID NO: 3, 18, ~~or~~ and 32.

Claims 4-5 (cancelled).

Claim 6 (currently amended): ~~[[An]]~~ The isolated and purified oxytocin secretion regulator according to Claim 1, which is ~~comprising~~ an oxytocin secretion promoter.

Claims 7-10 (cancelled).

Claim 11 (new): A method for manufacturing the oxytocin secretion regulator according to Claim 1, characterized by using a ligand peptide, consisting of (i) culturing transformants containing the DNA, encoding the oxytocin secretion regulator, and (ii) purifying the polypeptide from the transformant.

Claim 12 (new): A method for screening a compound regulating oxytocin secretion or a salt thereof, which is characterized by comparing (i) cases where contact is brought about between the receptor protein as claimed in Claim 1, or a salt thereof, and the ligand peptide as claimed in Claim 1, or a salt thereof, and (ii) cases where contact is brought about between the receptor protein as claimed in Claim 1, or a salt thereof, and a test compound, or a salt thereof, in the absence or presence of the ligand peptide as claimed in Claim 1, or a salt thereof.